Clinical trials: Ejection Fraction
Right Ventricular Ejection Fraction
Effect of Atrial Pacing on Right Ventricular Function After Cardiac Surgery
Temporary pacing with an external pacemaker after open heart surgery - besides preventing arrhythmias and AV-conduction disorders - is used to improve cardiac output.
- Trial name
- Outpace (NCT04151745)
- Testing
- external pacemaker switched off
- Sponsor
- Frisius Medisch Centrum
Heart Failure
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection…
- Trial name
- Aliskiren (NCT00982033)
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Wake Forest University Health Sciences
Systolic Heart Failure, Sudden Cardiac Death
A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)
The purpose of this study is to test the acceptability and feasibility of a "toolkit" of patient decision aids (PtDAs) for heart failure patients who are considering an ICD implant.
- Trial name
- NCT02026102
- Testing
- ICD Decision Aid Toolkit
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Colorado, Denver
Functional Tricuspid Regurgitation
Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction
Purpose Functional tricuspid regurgitation (FTR) has been shown to be associated with increased morbidity and mortality in several clinical conditions, including heart failure (HF) with reduced left ventricular ejection fraction…
- Trial name
- ECLIPSE-HF (NCT05209919)
- Testing
- Transthoracic Echocardiography
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Heart Failure With Reduced Ejection Fraction
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in…
- Trial name
- GOAL-HF1 (NCT05642507)
- Testing
- AC01
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 58 people
- Sponsor
- AnaCardio AB
COPD (Chronic Obstructive Pulmonary Disease), Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis
Study aim is comparison of heart failire with preserved ejection fraction (HFpEF) detection rate in patients with Сhronic Obstructive Pulmonary Disease (COPD) and the clinical course and prognosis in patients with COPD depending…
- Trial name
- HIPSTER (NCT07375433)
- Testing
- Echocardiography, Spirometry, Body plethysmography
- Where
- 2 sites in Russia
- Volunteers
- 200 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure, Essential Hypertension
LCZ696 in Advanced LV Hypertrophy and HFpEF
Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.
- Trial name
- NCT03928158
- Testing
- LCZ 696, Valsartan
- Where
- Russia
- Volunteers
- 61 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure With Preserved Ejection Fraction
Provocative Tests for HFpEF
Diagnosing heart failure with preserved ejection fraction (HFpEF) in patients complaining exertional breathlessness can be challenging: diagnostic algorithms and scores have low sensitivity, and ageing-associated comorbidities…
- Trial name
- TEST-PEF (NCT06309550)
- Testing
- exercise test
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Istituto Auxologico Italiano
AMI
Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI
Acute myocardial infarction (AMI) is one of the leading causes of death around the world, with the potential for substantial morbidity and mortality.
- Trial name
- BST-AMI (NCT05201274)
- Testing
- Baduanjin sequential therapy, Aerobic exercise
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shenyang Northern Hospital
Heart Failure
Sacubitril/Valsartan Versus Valsartan in Heart Failure
The objective of this study was to identify potential prognostic factors of sacubitril/valsartan vs Valsartan treatment response.
- Trial name
- NCT05881720
- Testing
- Sacubitril / Valsartan Oral Tablet, Valsartan 80 mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Damanhour University
Heart Failure With Normal Ejection Fraction
Renal Hemodynamics in Patients With HFpEF
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality.
- Trial name
- NCT03672591
- Testing
- Renal clearance examination
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Heart Failure Preserved Ejection Fraction, Pregnancy Complications
Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction
Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease.
- Trial name
- MAPO-HF (NCT06338943)
- Testing
- Echocardiography, Questionnaire
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure, Cardiomyopathy, Dilated
Ventricular Sling for Heart Failure With Reduced Ejection Fraction
The purpose of this research is to investigate the effect of using this surgical technique in conjunction with bypass surgery to improve heart function and size, as well as decrease the possibility of future mitral valve surgery.
- Trial name
- NCT04475315
- Testing
- Papillary Muscle Sling, CABG surgery
- Sponsor
- University of Miami
Heart Failure With Reduced Ejection Fraction
Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure
The Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure (ENIGMA-HF) study is a pragmatic parallel-arm randomized control trial of a quality improvement (QI) intervention involving email nudges to cardiology clinic…
- Trial name
- ENIGMA-HF (NCT05806970)
- Testing
- Email Nudge
- Where
- United States
- Sponsor
- University of California, Los Angeles
Coronary Artery Bypass, Cardiopulmonary Bypass
Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
Coronary artery disease has the highest mortality rate worldwide and coronary artery bypass grafting (CABG) is the most common cardiac surgery performed in patients with coronary artery disease to revascularize the heart.
- Conditions
- Coronary Artery Bypass, Cardiopulmonary Bypass, Coronary Artery Disease
- Trial name
- NCT04560309
- Testing
- L-alanyl-L-glutamine dipeptide
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Heart Failure, Obesity
Biomarkers in Patients With Suspected HFpEF
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1.
- Conditions
- Heart Failure, Obesity, Heart Failure With Preserved Ejection Fraction
- Trial name
- BIOPEF (NCT06101693)
- Testing
- Plasma biomarker levels
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,028 people
- Sponsor
- NHS Greater Glasgow and Clyde
Heart Failure, Reduced Ejection Fraction
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice
This is an observational, non-interventional, longitudinal prospective descriptive study including participants diagnosed with Heart Failure with reduced Ejection Fraction (HFrEF) in Italy and initiated on treatment with…
- Trial name
- EVOLUTION-HF (NCT05250011)
- Testing
- Dapagliflozin
- Where
- 11 sites in Italy
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Chronic Heart Failure
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection…
- Trial name
- NCT00887588
- Testing
- LCZ696, Valsartan
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 307 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Preserved Systolic Function
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart…
- Trial name
- PRESERVED-HF (NCT03030235)
- Testing
- Dapagliflozin 10Mg Oral Tablet
- Where
- 26 sites in United States
- Volunteers
- 324 people
- Sponsor
- Saint Luke's Health System
Type2 Diabetes, Heart Failure With Reduced Ejection Fraction
The Effects of SGLTi on Diabetic Cardiomyopathy
Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is considered as a cardiac muscle disorder secondary to diabetes mellitus (DM).
- Trial name
- SGLTi (NCT04200586)
- Testing
- Dapagliflozin
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.